SynBioBeta Speaker
Jenny Rooke
Genoa Ventures
Managing Director
Jenny Rooke is the Founder and Managing Director of Genoa Ventures, where she leverages her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to launch and empower the next generation of category-defying companies at the convergence of technology and biology. She has nearly two decades of investing experience beginning at Fidelity Biosciences in 2006 as a Kauffman Fellow. After Fidelity, Jenny helped establish the investing function at the Gates Foundation funding companies in genetic engineering, diagnostics, and synthetic biology. Jenny started what would become Genoa Ventures in 2014 using the largest life sciences syndicate on AngelList and achieving one of the highest-performing AngelList syndicates in any sector. Jenny’s investments and board seats at Genoa include Intabio (acquired by Danaher Sciex), InterVenn, Aqtual, Meiogenix, and BrightSpec. She also serves on the Board of Trustees of the Jackson Laboratory. Her prior investments include Zymergen (IPO), Caribou (IPO), Accuri (acquired by Becton Dickinson), and Topaz (acquired by Sanofi). Prior to her investing career, Jenny was a management consultant with McKinsey focused on the pharma and biotech sectors. She also served in executive management roles at U. S. Genomics leading Corporate Development and Research and Development. Jenny has a BS in Physics from the Georgia Institute of Technology and a Ph. D. in Genetics from Yale University.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jenny
This Year
•
-
TBD
Lightning Talk by Genoa Ventures
Get a Ticket
•
-
TBD
Lightning Talk by Genoa Ventures
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
